Sutimlimab shows promise for hard-to-treat, rare blood disorder

In a first-in-human clinical trial reported today in Blood, the investigational drug sutimlimab appeared to be effective in treating cold agglutinin disease, a rare chronic blood disorder for which there are currently no approved treatments. Cold agglutinin disease is caused by a malfunction in the immune system that causes antibodies - components of the immune system that are produced in the blood and help the body fight off disease - to mistakenly latch onto and kill red blood cells.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news